Trial Profile
A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2024
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 Jan 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.
- 16 Jan 2024 Planned primary completion date changed from 30 Nov 2023 to 31 Mar 2024.
- 30 Oct 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Nov 2023.